^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ladarixin (DF-2156A)
i
Other names: DF-2156A, DF-2156Y
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dompe
Drug class:
IL-8 inhibitor
Related drugs:
15d
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function (clinicaltrials.gov)
P2, N=140, Active, not recruiting, Dompé Farmaceutici S.p.A | Phase classification: P3 --> P2 | N=327 --> 140 | Trial primary completion date: Mar 2025 --> Apr 2024
Phase classification • Enrollment change • Trial primary completion date
|
ladarixin (DF-2156A)
4ms
Tumor-secreted extracellular vesicles counteract therapy response by triggering inflammatory mesenchymal stem cell development. (PubMed, Clin Cancer Res)
Our observations establish iMSCs as major contributors to drug resistance, reveal EVs as physiological triggers of iMSC development and highlight a promising combination strategy to improve therapy response in bone cancer patients.
Journal
|
IL6 (Interleukin 6) • TLR3 (Toll Like Receptor 3)
|
Actemra IV (tocilizumab) • ladarixin (DF-2156A)
8ms
Ladarixin With Sotorasib in Advanced NSCLC (clinicaltrials.gov)
P1, N=40, Recruiting, NYU Langone Health | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
over1year
Ladarixin With Sotorasib in Advanced NSCLC - Phase II (clinicaltrials.gov)
P2, N=0, Withdrawn, NYU Langone Health | N=28 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
over1year
Ladarixin With Sotorasib in Advanced NSCLC (clinicaltrials.gov)
P1/2, N=40, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2
Enrollment open • Phase classification • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
over1year
Ladarixin With Sotorasib in Advanced NSCLC - Phase II (clinicaltrials.gov)
P2, N=28, Not yet recruiting, NYU Langone Health
New P2 trial • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
over1year
Ladarixin With Sotorasib in Advanced NSCLC - Phase I (clinicaltrials.gov)
P1, N=12, Not yet recruiting, NYU Langone Health
New P1 trial • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
2years
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. (PubMed, Br J Cancer)
Ladarixin in combination with anti-PD-1 might represent an extremely effective approach for the treatment of immunotherapy refractory PDAC, allowing pro-tumoral to immune-permissive microenvironment conversion.
Journal
|
CXCR1 (Chemokine (C-X-C motif) receptor 1)
|
ladarixin (DF-2156A)
Share via
